Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Kim N.; Dana E. Rathkopf; Matthew R. Smith; Eleni Efstathiou; Gerhardt Attard; David Olmos; Ji Youl Lee; Eric J. Small; Andrea Juliana Gomes; Guilhem Roubaud; Marniza Saad; Bogdan Żurawski; V.S. Sakalo; Gary Mason; Peter Francis; George Wang; Daphne Wu; Brooke Diorio; Angela Lopez‐Gitlitz; Shahneen Sandhu; María Alejandra Álvarez; Gabriela Gatica; Martín Greco; Ernesto Korbenfeld; Esteban Metrebián; Jorge Salinas; Alejandro Salvatierra; Marcelo Tatangelo; Tom Ferguson; Howard Gurney; Elizabeth Hovey; Anthony M. Joshua; Matos Marco; Gavin Marx; Michelle Morris; Siobhan Ng; David Pook; Shahneen Sandhu; Ali Tafreshi; Thean Hsiang Tan; Tsvetanka Tosheva; Livia Andrade; Felipe Melo Cruz; Luiza Dib Batista Bugiato Faria; J. M. L. Figueiredo; Fábio Franke; Andrea Juliana Gomes; Ariel Galapo Kann; Celio Kussumoto; Suelen Patrícia dos Santos Martins; André M. Murad; Hélio Pinczowski; Giovani Thomaz Pioner; Luís Ferreira Pires; Daniel D’Almeida Preto; Gisele Marinho dos Santos; Eduardo Silva; Jamile Silva; Luciano de Souza Viana; Karina Vianna; Adriano Augusto Peclat de Paula; Zhiwen Chen; Kim Chi; Urban Emmenegger; Neil Fleshner; Sunil Parimi; Fred Saad; Francisco Vera-Badillo; Hongqian Guo; Lulin Ma; Mingxing Qui; Wei Xue; Yong-Lian Guo; Lei Li; Jinxian Pu; Song Zheng; Qing Zou; Miloš Broďák; Milan Hora; Vladimír Šámal; Vladimír Študent; J Vaňásek; Emmanuelle Bompas; Philippe Barthélémy; Delphine Borchiellini; Aude Fléchon; Hakim Mahammedi; Guilhem Roubaud; Antoine Thiery-Vuillemin; Diégo Tosi; Dominique Spaëth; Carole Hélissey; Martin Boegemann; Susan Feyerabend; Eva Hellmis; Martin Schostak; Gerhardt Attard; Anna Lydon; Ian Sayers; Hong Luo

doi:10.1200/jco.22.01649

Article2022

Tumor Genomic Testing for &gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Joaquı́n Mateo, David Olmos, Niven Mehra, Michael Paul Kolinsky, Guilhem Roubaud, Mustafa Özgüroğlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman, A. Allen, Christian Poehlein, Johann S. de Bono

Article2022

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer

Andrisha–Jade Inderjeeth, Monique Topp, Elaine Sanij, Elena Castro, Shahneen Sandhu

Preprint2023

Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Joaquı́n Mateo, David Olmos, Niven Mehra, Michael Paul Kolinsky, Guilhem Roubaud, Mustafa Özgüroğlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman,

Preprint2023

Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Maha Hussain, Claire Corcoran, Caroline Sibilla, Karim Fizazi, Fred Saad, Neal D. Shore, Shahneen Sandhu, Joaquı́n Mateo, David Olmos, Niven Mehra, Michael Paul Kolinsky, Guilhem Roubaud, Mustafa Özgüroğlu, Nobuaki Matsubara, Craig Gedye, Young Deuk Choi, Charles Padua, Alexander Kohlmann, Robert Huisden, Julia A. Elvin, Jinyu Kang, Carrie A. Adelman,

Article2017

PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.

Johann S. de Bono, Maha Hussain, Antoine Thiery-Vuillemin, Joaquı́n Mateo, Oliver Sartor, Kim N., Karim Fizazi, Przemyslaw Twardowski, Neeraj Agarwal, Shahneen Sandhu, David Olmos, Neal D. Shore, Fred Saad, Sherry Liu, Carsten Goessl, Joe Burgents

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Abstract

Discussion(0)

Related publications

Tumor Genomic Testing for &gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer

Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Abstract

Discussion(0)

Related publications

Tumor Genomic Testing for &amp;gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Clinical Application of Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Prostate Cancer

Data from Tumor Genomic Testing for &gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Data from Tumor Genomic Testing for &gt;4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

PROfound: A randomized Phase III trial evaluating olaparib in patients with metastatic castration-resistant prostate cancer and a deleterious homologous recombination DNA repair aberration.

Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)

Data from Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib)